DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Mahavir Advanced Remedies Ltd

111489·BSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

N/A

P/E Ratio

N/A

P/B Ratio

N/A

EPS

₹0.12

Book Value

N/A

ROE

1.61%Weak

ROCE

1.61%Weak

Dividend Yield

N/A

Debt / Equity

N/A

Face Value

₹10.00

52W High

N/A

52W Low

N/A

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Fairly Valued

None moatHigh uncertainty

Fair value unavailable

/100

Business quality — Watch the fundamentals

Growth 50Profitability 50Efficiency 0Valuation 50

Plain English

Our view

A steady, established business
Weak returns on equity (2%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

1.6%Weak

Above 15% is considered healthy for Indian equities

ROCE

1.6%Weak

Above 18% means capital is working hard

Debt/Eq

—

Mkt Cap

—

P/B

—

EPS

₹0.12

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

N/A

No history

Profitability

Modest

1.6% ROE

Financial health

N/A

No debt data

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

No growth history

Not enough annual history to compute CAGR.

Profile

Pros

Company is almost debt free.

Watch-outs

Cons

Stock is trading at 19.2 times its book value
Company has a low return on equity of -2.33% over last 3 years.
Working capital days have increased from 17,954 days to 30,258 days

Forecast

News

Peers

Financials

Growth

Shareholding

No shareholding data

Ownership data is not available for this instrument.

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Mahavir Advanced Remedies Ltd is an India-based manufacturer and trading of tablet, liquid orals, capsules and ointments.